<DOC>
	<DOCNO>NCT03074149</DOCNO>
	<brief_summary>To gain insight characteristic , management , disease progression outcomes patient IPF , diagnose treat real-world , clinical practice condition Greece . More specifically , registry use : Provide comprehensive clinical picture IPF , Track access health care cost care IPF patient time , Examine implementation treatment guideline use patient diagnosed IPF , accord exist diagnosis guideline , Characterization patient different treatment . To provide information regard survival mortality cause , IPF exacerbation well IPF patient co-morbidities include myocardial infarction , CNS infarction , arterial thromboembolic event , deep vein thrombosis , hemorrhage , gastrointestinal perforation pulmonary hypertension . Data regard IPF patient hospitalization collect evaluated regard potential respiratory cause , documentation treatment pattern economic aspect . Patients follow 2 year information regard IPF treatment change since last visit collect .</brief_summary>
	<brief_title>Investigating Idiopathic Pulmonary Fibrosis Greece ( INDULGE IPF )</brief_title>
	<detailed_description>Purpose : To gain knowledge characteristic , management , progression outcome patient IPF treat real-world , clinical practice condition Greece Study Design : National , multi-center , observational disease registry base new data significant sample size IPF patient Greece . Patients follow 2 year information collect time period . This non-interventional study primary data collect study visit use</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Inclusion criterion : Newly diagnose ( less 6 month ) patient previously diagnose IPF ( 6 month baseline visit ) , base upon consensus statement jointly issue ATS/ERS/JRS/ALAT 2011 ( see Annexes 6 7 HRCT histological criterion Annex 6 ) Exclusion know cause ILD ( e.g. , domestic occupational environmental exposure , connective tissue disease , drug toxicity ) Assessment IPF base HRCT combination HRCT surgical lung biopsy , available Age =40 year old time inclusion Written inform consent participation registry Patients follow , schedule study period Exclusion criterion : Expected lung transplantation within follow 6 month Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>